Adjuvant TKIs in NSCLC: what can we learn from RADIANT?
- PMID: 26552954
- DOI: 10.1038/nrclinonc.2015.202
Adjuvant TKIs in NSCLC: what can we learn from RADIANT?
Comment on
-
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.J Clin Oncol. 2015 Dec 1;33(34):4007-14. doi: 10.1200/JCO.2015.61.8918. Epub 2015 Aug 31. J Clin Oncol. 2015. PMID: 26324372 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical